Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease

Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: Luukkonen, Panu K., Tukiainen, Taru, Juuti, Anne, Sammalkorpi, Henna, Haridas, P.A. Nidhina, Niemelä, Onni, Arola, Johanna, Orho-Melander, Marju, Hakkarainen, Antti, Kovanen, Petri T., Dwivedi, Om, Groop, Leif, Hodson, Leanne, Gastaldelli, Amalia, Hyötyläinen, Tuulia, Orešič, Matej, Yki-Järvinen, Hannele
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7141400/
https://ncbi.nlm.nih.gov/pubmed/32161197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.132158
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi